Nirmidas Biotech, Inc. - an Alumni of JLab San Francisco - provides solutions for bio-analytical and diagnostic researchers using plasmonic gold (pGOLD) technology that - optimized over nearly a decade of research - vastly enhances near-infrared fluorescence signal. Nirmidas Biotech and Stanford University have collaborated to develop a multiplexed serological test for the diagnosis of Zika and Dengue. More recently the firm has developed, validated, and launched the COVID-19 rapid test for IgG/IgM for clinical diagnostics with Nimrmidas' technology being based on a novel red to near-infrared fluorescence enhancing detection platform. The platform is a personal and portable diagnostic systems for early disease diagnosis and prognosis monitoring, as well as for population-based screening applications. One of the company's primary technologies is a near-infrared II (NIR-II) dye product (IR-E1050) with high quantum yield and high biocompatibility (renal excretion) which can be used for fluorescence imaging with low autofluorescence/low background ex vivo with cells and tissues. Nirmidas is resident at Janssen Labs @QB3 as well as StartX Med, a Stanford-affiliated nonprofit technology accelerator program.
